But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.